AstraZeneca PLC (AZN) Financial Statements
Historical financial data — 5 statements covering FY2021–FY2025
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% o...
AstraZeneca PLC's revenue increased 8.6% year over year, from $54.07B to $58.74B.
Net income increased 45.3% over the same period, from $7.04B to $10.22B.
Over the 4-year period from FY2021 to FY2025, revenue grew by 57% in total.
Total debt remained relatively stable at $29.62B.
The debt-to-equity ratio stands at 0.61, indicating a moderate leverage profile.
AstraZeneca PLC maintains a healthy net profit margin of 17.4%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2021 | $37.42B | $112.0M | $24.98B | $1.06B | N/A | $105.36B | $30.78B | $39.29B |
| FY2022 | $44.35B+18.5% | $3.29B | $31.96B | $3.76B | N/A | $96.48B | $29.23B | $37.06B |
| FY2023 | $45.81B+3.3% | $5.96B | $37.54B | $8.19B | N/A | $101.12B | $28.62B | $39.17B |
| FY2024 | $54.07B+18.0% | $7.04B | $43.87B | $10.00B | N/A | $104.03B | $30.30B | $40.87B |
| FY2025 | $58.74B+8.6% | $10.22B | $48.11B | $13.74B | N/A | $114.07B | $29.62B | $48.72B |
Balance Sheet Summary (Latest Period)
Total Assets
$114.07B
Total Liabilities
$65.36B
Total Equity
$48.72B
Cash & Equivalents
$5.74B
Total Debt
$29.62B
Current Assets
$28.72B
Current Liabilities
$30.62B
Retained Earnings
$10.97B